SEC Form 4 · accession 0001127602-16-054955
LEXICON PHARMACEUTICALS, INC. · LXRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James F Tessmer
Officer — VP, Finance & Accounting
Period of report
Jun 6, 2016
Accepted (ET)
Jun 8, 2016 · 8:22 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001062822
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 6, 2016 | M | 1,500 | $6.23 | A | 17,446 | D | |
| Common Stock | Jun 6, 2016 | S | 1,500 | $15.00 | D | 15,946 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $6.23 | Jun 6, 2016 | M | 1,500 | D | — | Feb 5, 2025 | Common Stock | 1,500 | 17,399 | D |
Explanation of responses
- F1Effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Tessmer on May 16, 2016.
- F2Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/5/16) and vests 1/48th per month for each month of service thereafter.